ALLO

Allogene Therapeutics, Inc.
CAPPED RATING

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics, Inc. (ALLO) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (D+). The rating has held at C+ for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.6 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.3
EV / EBITDA -0.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -60.1%
Price Return 12M -32.5%
Catalyst Signal 0.00
Market Cap $279.6M
TTM Revenue $4.6M
Price / Sales 60.3
ROE -49.3%

Historical Factor Score Progression

Held C+ for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.6) B (3.3) C (2.4) D+ (1.6) C+ (2.6) C+ (2.5)
2026-11-10 C (2.5) B (3.3) C (2.4) C- (1.9) C+ (2.6) C+ (2.5)
2026-11-03 C (2.5) B (3.2) C (2.4) D+ (1.8) C+ (2.7) C+ (2.5)
2026-10-27 C (2.5) B (3.2) C (2.5) C- (2.1) C+ (2.6) C+ (2.6)
2026-10-20 C (2.4) B (3.2) C (2.5) C- (2.0) C+ (2.6) C+ (2.5)
Page 1 of 7